clinical trial · NCT05639400
Thoraflex Hybrid and Relay Extension Post-Approval Study
Vascutek Ltd.·—·active not recruiting·n = 352
Thoracic DiseasesAortic AneurysmAortic DissectionThoracic Aortic AneurysmThoracic Aortic DissectionThoraflex HybridRelayPro NBS
brief summary
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site. Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed.
started
Mar 17, 2023
primary completion
Jul 1, 2035
completion
Mar 1, 2036
last updated
Feb 6, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol